Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Liabilities and Shareholders Equity: 2020-2024

Historic Liabilities and Shareholders Equity for Biofrontera (BFRI) over the last 5 years, with Dec 2024 value amounting to $22.1 million.

  • Biofrontera's Liabilities and Shareholders Equity fell 16.75% to $15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.2 million, marking a year-over-year decrease of 19.82%. This contributed to the annual value of $22.1 million for FY2024, which is 20.88% down from last year.
  • As of FY2024, Biofrontera's Liabilities and Shareholders Equity stood at $22.1 million, which was down 20.88% from $27.9 million recorded in FY2023.
  • Biofrontera's Liabilities and Shareholders Equity's 5-year high stood at $53.2 million during FY2021, with a 5-year trough of $22.1 million in FY2024.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $27.9 million (2023), whereas its average is $33.6 million.
  • Per our database at Business Quant, Biofrontera's Liabilities and Shareholders Equity surged by 120.48% in 2021 and then plummeted by 45.11% in 2023.
  • Yearly analysis of 5 years shows Biofrontera's Liabilities and Shareholders Equity stood at $24.1 million in 2020, then spiked by 120.48% to $53.2 million in 2021, then decreased by 4.39% to $50.9 million in 2022, then plummeted by 45.11% to $27.9 million in 2023, then decreased by 20.88% to $22.1 million in 2024.